About Dr. Zhou Caicun
Dr. Zhou Caicun (周彩存) is Chief Physician, Professor, and Director of the Department of Medical Oncology at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine — China's foremost thoracic specialty center and the national benchmark for lung cancer diagnosis and treatment. He is one of China's most internationally recognized lung cancer oncologists, with a career spanning more than three decades of clinical practice, landmark clinical trial leadership, and contributions to global treatment guideline development.
Dr. Zhou's clinical philosophy is rooted in molecular precision: every patient's tumor is profiled at the genomic level before treatment decisions are made. His department performs comprehensive next-generation sequencing (NGS) panels covering EGFR, ALK, ROS1, KRAS G12C, MET exon 14, RET, NTRK, HER2, and emerging targets, enabling the most accurate matching of patients to approved targeted agents or investigational therapies. For patients who have progressed on prior targeted therapy, Dr. Zhou's expertise in resistance mechanism analysis — including liquid biopsy-guided ctDNA monitoring — allows rapid adaptation of treatment strategy to stay ahead of evolving disease.
Beyond his clinical work, Dr. Zhou has served as principal investigator in multiple pivotal Phase III trials that have directly contributed to global regulatory approvals for targeted therapies in non-small cell lung cancer (NSCLC). His research has been published in The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology, and presented at ASCO, ESMO, WCLC, and IASLC. He is a member of the Chinese Society of Clinical Oncology (CSCO) lung cancer expert committee and a key contributor to China's national lung cancer treatment guidelines.
Hospital Affiliation: Shanghai Chest Hospital
Shanghai Chest Hospital (上海市胸科医院) is China's most specialized and highest-volume thoracic disease center, dedicated exclusively to diseases of the chest. Founded in 1957 and affiliated with Shanghai Jiao Tong University School of Medicine, it is the national leader in lung cancer surgery, medical oncology, radiation oncology, and interventional pulmonology. The hospital performs more lung cancer operations and manages more advanced lung cancer cases than any other center in China.
The Department of Medical Oncology at Shanghai Chest Hospital integrates seamlessly with thoracic surgery, radiation oncology, interventional pulmonology, and molecular pathology to deliver multidisciplinary lung cancer care at the highest level. The hospital's molecular pathology laboratory provides rapid, comprehensive genomic profiling with turnaround times that support timely clinical decision-making. The active clinical trials program offers patients access to investigational agents and combination regimens not yet commercially available in their home countries.
Clinical Expertise
- EGFR-mutant NSCLC — first, second, and third-generation EGFR TKIs including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib; management of T790M and C797S resistance mutations; osimertinib-resistant disease strategies
- ALK/ROS1 rearrangement — crizotinib, alectinib, brigatinib, lorlatinib; management of ALK resistance; ROS1-directed therapy
- KRAS G12C mutation — sotorasib, adagrasib; combination strategies for KRAS-mutant NSCLC
- MET exon 14 skipping & MET amplification — tepotinib, capmatinib, savolitinib; MET-directed combination therapy
- RET fusion & NTRK fusion — selpercatinib, pralsetinib; larotrectinib, entrectinib
- HER2 mutation — trastuzumab deruxtecan (T-DXd); HER2-directed combination regimens
- Immunotherapy — PD-1/PD-L1 checkpoint inhibitor monotherapy and combination chemo-immunotherapy; immunotherapy for special populations including EGFR-mutant, brain metastases, and elderly patients; biomarker-driven immunotherapy selection (PD-L1, TMB, MSI)
- Advanced and metastatic NSCLC — first-line and subsequent-line systemic therapy; oligometastatic disease management; brain and leptomeningeal metastasis treatment; bone metastasis management
- Small cell lung cancer (SCLC) — extensive-stage SCLC; immunotherapy combinations (atezolizumab, durvalumab); relapsed/refractory SCLC; prophylactic cranial irradiation coordination
- Resistance mechanism analysis — liquid biopsy and ctDNA-guided treatment adaptation; next-generation sequencing of re-biopsy specimens; management of on-target and off-target resistance mechanisms
- Clinical trial access — investigational targeted agents, novel immunotherapy combinations, and antibody-drug conjugates (ADCs) through Shanghai Chest Hospital's active Phase I–III trials program
Academic Leadership & Research Contributions
Dr. Zhou Caicun is one of China's most prolific and internationally impactful lung cancer researchers. He has authored and co-authored hundreds of peer-reviewed publications, with a research focus on precision oncology, targeted therapy outcomes, immunotherapy biomarkers, and resistance mechanisms in NSCLC. His work as principal investigator in pivotal clinical trials has directly shaped the global evidence base for targeted therapy in lung cancer, and his publications are widely cited in international treatment guidelines.
He is a recognized key opinion leader at major international oncology congresses including ASCO Annual Meeting, ESMO Congress, World Conference on Lung Cancer (WCLC), and IASLC. Dr. Zhou is also a leading voice in the field of liquid biopsy and ctDNA-guided treatment monitoring, and has contributed to the development of consensus recommendations for molecular testing in lung cancer in China and internationally.
His academic leadership extends to mentorship of the next generation of thoracic oncologists at Shanghai Chest Hospital, and he has established collaborative research relationships with leading cancer centers in the United States, Europe, and Asia-Pacific.
Why International Patients Choose Dr. Zhou Caicun
For international patients with advanced or metastatic lung cancer — particularly those with actionable molecular alterations, rare driver mutations, or disease that has progressed on prior targeted therapy — Dr. Zhou's program at Shanghai Chest Hospital offers a combination of precision oncology expertise, clinical trial access, and treatment speed that is genuinely world-class.
Patients who have exhausted standard treatment options in their home countries, or who are seeking a second opinion on a complex molecular profile, frequently find new treatment pathways through Dr. Zhou's program. His team's experience with rare driver mutations (MET, RET, NTRK, HER2), complex resistance scenarios (post-osimertinib, post-lorlatinib), and novel combination regimens means that even the most challenging cases are approached with a structured, evidence-based strategy.
Treatment costs at Shanghai Chest Hospital are substantially lower than equivalent oncology care in Western healthcare systems — typically 30–60% less for equivalent targeted therapy regimens — with no compromise in diagnostic accuracy, treatment expertise, or supportive care quality. For patients with rapidly progressing disease, the speed of access from initial consultation to treatment initiation is typically far faster than in public healthcare systems abroad, and this speed advantage can be clinically significant in aggressive disease settings.
CMCS has coordinated oncology consultations and treatment programs for patients from North America, Europe, Southeast Asia, the Middle East, and Oceania through Dr. Zhou's department, and our team has deep familiarity with the logistics, documentation, and communication requirements of international patients seeking care at Shanghai Chest Hospital.
What to Expect at Your Consultation
Consultations with Dr. Zhou begin with a comprehensive review of all prior pathology reports, molecular testing results (NGS panels, FISH, IHC), imaging studies (CT, PET-CT, MRI), and complete treatment history including prior targeted agents, chemotherapy regimens, and immunotherapy. CMCS will arrange certified translation of all medical records and imaging reports into Chinese in advance of the consultation, ensuring that Dr. Zhou's team can review your complete case without delay.
During the consultation, Dr. Zhou will assess whether additional molecular profiling or re-biopsy is indicated, outline the recommended treatment strategy with rationale, discuss clinical trial eligibility, and provide a clear explanation of expected outcomes, monitoring plan, and follow-up schedule. For patients unable to travel to Shanghai for an initial consultation, CMCS can arrange a video consultation with Dr. Zhou's team to review records and provide a preliminary treatment recommendation before the patient travels.
A written English-language consultation summary is provided after every appointment, documenting the diagnosis, molecular profile, recommended treatment plan, and next steps. This summary can be shared with the patient's oncologist at home to facilitate coordinated care.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking oncology consultation and treatment with Dr. Zhou Caicun at Shanghai Chest Hospital. Our services include priority consultation and treatment scheduling, certified medical record translation, pre-consultation imaging and pathology review, treatment logistics and pharmacy coordination, on-site interpretation during consultations and procedures, accommodation and transport arrangements, and ongoing follow-up coordination between Dr. Zhou's team and the patient's home oncologist.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 commenti